Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYCLOSPORINE-A INCREASES THE BIOCHEMICAL MARKERS OF BONE REMODELING IN PRIMARY BILIARY-CIRRHOSIS
Autore:
GUANABENS N; PARES A; NAVASA M; DEOSABA MJM; HERNANDEZ ME; MUNOZ J; RODES J;
Indirizzi:
HOSP CLIN BARCELONA,SERV RHEUMATOL,METAB BONE DIS UNIT,VILLARROEL 170E-08036 BARCELONA SPAIN HOSP CLIN BARCELONA,LIVER UNIT BARCELONA SPAIN
Titolo Testata:
Journal of hepatology
fascicolo: 1, volume: 21, anno: 1994,
pagine: 24 - 28
SICI:
0168-8278(1994)21:1<24:CITBMO>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLA-PROTEIN; CIRCULATING OSTEOCALCIN; LIVER-TRANSPLANTATION; RESORPTION; RAT; CALCIUM; INVITRO; OSTEOPOROSIS; METABOLISM; INHIBITION;
Keywords:
BONE MINERAL METABOLISM; BONE MASS; HYDROXYPROLINE/CREATININE INDEX; OSTEOCALCIN; PARATHYROID HORMONE; VITAMIN-D;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
N. Guanabens et al., "CYCLOSPORINE-A INCREASES THE BIOCHEMICAL MARKERS OF BONE REMODELING IN PRIMARY BILIARY-CIRRHOSIS", Journal of hepatology, 21(1), 1994, pp. 24-28

Abstract

To assess whether cyclosporin A has any influence on the bones of patients with primary biliary cirrhosis, bone mineral density, vertebral fractures and biochemical and hormonal parameters of bone mineral metabolism were evaluated in 38 female patients with primary biliary cirrhosis who, 7 to 47 months previously, had been randomized to receive cyclosporin A (n=18) or placebo (n=20). Bone mineral density and vertebral fractures were reevaluated after 12 to 47 months in 19 of these patients (ten with cyclosporin and nine with placebo). Serum osteocalcin levels in patients taking cyclosporin (median, range: 7.8, 4.2-16 ng/ml) were similar to healthy female controls (6.0, 4.7-9.5 ng/ml), and significantly higher than in patients receiving placebo (5.4, 1.0-8.6 ng/ml, p<0.02). Patients treated with cyclosporin showed a higher urinary hydroxyproline/creatinine ratio (0.097, 0.025-0.138) than patients with placebo (0.031, 0.022-0.044) (0.05> p<0.1), and healthy controls (0.032, 0.021-0.048) 01<0.001). Urinary hydroxyproline was above normal levels in six of nine patients treated with cyclosporin. Circulatingparathyroid hormone levels were also higher in patients treated with cyclosporin (4.3, 2.0-9.0 pmol/l) than in those with placebo (3.1, 1.1-5.1 pmol/l) (p<0.001), and healthy controls (2.9, 1.1-6.9 pmol/ 1) (p<0.001). In four patients treated with cyclosporin the parathyroid hormone levels were above normal values. No patient had renal failure. Among the 19 patients who were studied on two occasions, no significant bone mineral density changes were observed in ten patients treated with cyclosporin (1.012, 0.693-1.269 vs 0.990, 0.710-1.237 g/cm(2), p:n.s), whereas bone mineral density decreased significantly in nine patients who received placebo (0.984, 0.912-1.374 vs 0.914, 0.781-1.006 g/cm(2), p<0.05). One patient who had received placebo developed a new vertebral fracture within 6 months after the end of the trial. This studyindicates that cyclosporin A increases the biochemical parameters of bone remodeling, and prevents bone loss in patients with primary biliary cirrhosis. (C) Journal of Hepatology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 16:03:50